December 11, 2014
A Pennsylvania transportation agency has hit Gilead Sciences Inc. with a class action over its hepatitis C drug Sovaldi, claiming that the pharmaceutical giant is maintaining a questionable monopoly on the medicine and price-gouging customers for it, as well as running afoul of the Affordable Care Act.